Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
E: investors@grifols.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,800
Grifols SA News & Analysis
stocks
6 undervalued stocks with low beta
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 81.90 | -0.91% |
| CAC 40 | 7,632.48 | 139.49 | -1.79% |
| DAX 40 | 23,651.97 | 413.50 | -1.72% |
| Dow JONES (US) | 44,130.98 | 330.30 | -0.74% |
| FTSE 100 | 9,085.55 | 47.26 | -0.52% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 21,122.45 | 7.23 | -0.03% |
| Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
| NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
| S&P 500 | 6,339.39 | 23.51 | -0.37% |
| S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |